



FRONTIERS IN ONCOLOGIC PROSTATE CARE AND ABLATIVE LOCAL THERAPY

October 17 - 19

Manchester Grand Hyatt San Diego



Dear Friends and Colleagues,

We welcome new and prior attendees to Frontiers in Oncologic Prostate Care and Ablative Local Therapy, FOCAL+2024. This year, we have a renewed program that incorporates additional education in the ever-changing advanced prostate cancer landscape. The expanding indications of systemic therapies have made it essential knowledge in the management of prostate cancer. We are excited to offer again three hands-on training workshops on inoffice transperineal interventions, fusion-quided prostate ablation, and state-of-the-art BPH management, providing an immersive experience led by key opinion leaders.

We are honored to host our Keynote Speaker, Dr. Ralph Clayman, Chair and Dean Emeritus at the University of California, Irvine. Dr. Clayman is an educator and innovator whose contributions in the field of minimally invasive urology has shaped our field.

As the content of this meeting continues to grow, we hope to continue to engage new and early users with varying levels of experience to provide contemporary content relevant to diverse audiences.

We would also like to take this opportunity to thank our industry partners. Each year we are able to create dynamic and innovative offerings due to their support of our mission and this meeting. We are confident that this program will be an outstanding educational experience and will help us continue to grow this pioneering field together. Please take some time to enjoy the wonderful property and wonderful city of San Diego while you are at FOCAL+ 2024.

Warm regards,

Arvin K. George, MD

Program Director

Abhinav Sidana, MD, MPH Program Director



FOCAL 2024 FACULTY



Arvin K. George, MD



Abhinav Sidana, MD, MPH



Ralph Clayman, MD - Keynote Speaker



Andre Abreu, MD





Aaron Berger, MD



Giovanni Cacciamani, MD, MSc, FEBU



Bilal Chughtai, MD





John Michael DiBianco, MD Jonathan Fainberg, MD, MPH



Amin S. Herati, MD



Juan Javier-DesLoges, MD, MS



Veeru Kasivisvanathan, MBBS, BSc, FRCS, PhD, MSc, PGCert





Amir Lebastchi, MD



Herbert Lepor, MD



Stacy Loeb, MD, MSc, PhD (Hon)



Derek Lomas, MD





Nicole Miller, MD, FACS



Ruben Olivares, MD



Peter Pinto, MD



Arun Rai, MD



Natalie Reizine, MD



Michael Rothberg, MD



Steven Rowe, MD, PhD,



Ilya Sobel, MD



Daniel Song, MD







Sadhna Verma MD, MBA, FSAR



Karla Witzke, DO



Richard Wu, MD




James Wysock, MD



Kevin Zorn, MD, FRCSC, FACS

Second Level







INDUSTRY SPONSORED PRODUCT THEATERS

Seaport Ballroom F-G

LUNCH • THURSDAY, OCTOBER 17 • 12:15 pm – 12:45 pm

ECOSYSTEM FOR PROSTATE CANCER CARE CYCLE MANAGEMENT

Paavo Immonen

Product Management Lead DMS



BREAKFAST • FRIDAY, OCTOBER 18 • 7:00 am - 7:45 am

TRANSPERINEAL PROSTATE BIOPSIES WITH NEW TP PIVOT PRO™

Marci Tucker

RDMS RVT - Clinical Specialist

Josh Abdo

Sr. Product Manager HLD & Urology PLM



LUNCH • FRIDAY, OCTOBER 18 • 12:00 pm - 1:00 pm

SONABLATE: NOT ALL HIFU IS THE SAME

Andre Abreu, MD

Assistant Professor of Clinical Urology, Keck Medicine of USC

Thomas Frye, DO

Associate Professor of Urology, University of Rochester Medical Center

Jack Sells

CEO Sales Search America and Prostate Cancer Patient



LUNCH • SATURDAY, OCTOBER 19 • 12:00 pm - 1:00 pm

THE VALUE OF 3D MAPPING AND TREATMENT GUIDANCE USING OBT FUSION IN PREPARATION OF FOCAL THERAPY

Julien Anract, MD



BIOPSY MAP FUSION-GUIDED PARTIAL-GLAND ABLATION WITH FOCAL ONE

Andre Abreu, MD

Keck Medicine of USC





THURSDAY, OCTOBER 17

	BREAKFAST ON YOUR OWN
6:30 am – 6:00 pm	Registration & Information • Seaport Foyer
SESSION 1: PROSTATE IMAGING, SAMPLING AND SPACING	
8:00 am	Welcome - Arvin K. George, MD
8:05 am	PIRADS V2.1 - What a Urologist Needs to Know? Sadhna Verma, MD, MBA, FSAR
8:25 am	Can Imaging Replace Prostate Biopsy - Primary Detection, Active Surveillance and Recurrent PCa? Veeru Kasivisvanathan, MBBS, BSc, FRCS, PhD, MSc, PGCert
8:40 am	Discussion
8:50 am	PET Scanning in Primary Detection of Prostate Cancer Steven Rowe, MD, PhD
9:05 am	PSMA PET for Preoperative Planning of Prostate Cancer: Nodes, Nerves and Margins James Wysock, MD
9:15 am	Discussion
9:25 am	Transperineal vs Transrectal Biopsy Clinical Trials: Mo' Data Mo' Problems Arvin K. George, MD
9:40 am	Point Counterpoint: Risk Stratification for Biopsy MRI: Peter A. Pinto, MD
	Biomarkers: Juan Javier-DesLoges, MD, MS, MD
9:55 am	Rectal Spacer Abhinav Sidana, MD, MPH
10:05 am - 10:35 am	COFFEE BREAK WITH EXHIBITORS • Seaport Ballroom ABC
	SESSION 2: ARTIFICIAL INTELLIGENCE
10:35 am	Introduction to AI in Healthcare Giovanni Cacciamani, MD, MSc, FEBU
10:55 am	Al and Prostate Imaging and Biopsy Baris Turkbey, MD
11:15 am	Al and Treatment Planning for Prostate Cancer Andre Abreu, MD
11:30 am	Pragmatic Applications of AI in Urology Practice Arun Rai, MD
11:45 am	Panel Discussion: Artificial Intelligence in Prostate Cancer Moderator Giovanni Cacciamani, MD, MSc, FEBU Panelists Andre Abreu, MD, Baris Turkbey, MD, Arun Rai, MD
12:15 pm – 12:45 pm	LUNCH • Industry Sponsored Product Theater • Seaport Ballroom ABC
12:45 pm – 1:15 pm	Exhibit Hall Open
1:15 pm – 5:45 pm	ADVANCED PROSTATE CANCER MASTERCLASS
1:15 pm	Course Introduction: Description of Terminology and Review of Guidelines Natalie Reizine, MD
1:35 pm	Genetic Testing in Prostate Cancer Management Abhinav Sidana, MD, MPH
1:50 pm	Optimal Management of Biochemically Recurrent Nonmetastatic Prostate Cancer Aaron Berger, MD
2:00 pm	Discussion
2:10 pm	Metastatic Castrate Sensitive Prostate Cancer Rana McKay, MD
2:30 pm	SBRT for Mets: Rationale and Evidence Daniel Song, MD
2:40 pm	

All times listed in PT
Plenary Session • Seaport Ballroom DE

THURSDAY, OCTOBER 17 continued

3:10 pm - 3:40 pm	COFFEE BREAK WITH EXHIBITORS • Seaport Ballroom ABC
3:40 pm	Urologist Led Advanced Prostate Cancer Practice: Tips, Tricks and Pitfalls Aaron Berger, MD
4:00 pm	Metastatic Castrate Resistant Prostate Cancer- Immunotherapy and Parp Inhibitors Alan Tan, MD
4:20 pm	Discussion
4:30 pm	Challenging Cases Natalie Reizine, MD, Alan Tan, MD
5:10 pm	Radiopharmaceuticals in Advanced Prostate Cancer Steven Rowe, MD, PhD
5:30 pm	Discussion
5:40 pm	Conclusion - Natalie Reizine, MD

FRIDAY, OCTOBER 18

* Ticketed Hands-On Course. Additional fee applies.

6:30 am – 6:00 pm	Registration & Information • Seaport Foyer
7:00 am – 7:45 am	BREAKFAST • Industry Sponsored Product Theater • Seaport Ballroom FG
	*HANDS-ON COURSE I • STATE-OF-THE-ART BPH MANAGEMENT
8:00 am	Welcome & Introduction John Michael DiBianco, MD
8:05 am	Surgical BPH: 2024 Updates and Where Are We Going Nicole Miller, MD
8:15 am	Office BPH: 2024: Updates and Where Are We Going Kevin Zorn, MD, FRCSC, FACS
PART 1 • Prostate Cancer	Considerations Before and After BPH
8:25 am	Elevated PSA and Obstructive LUTS <i>Bilal Chughtai</i> , <i>MD</i>
8:35 am	Obstructive LUTS and Known Prostate Cancer Kevin Zorn, MD, FRCSC, FACS
8:45 am	Prostate Cancer after BPH Treatment Ilya Sobol, MD
8:55 am	Discussion
PART 2 • Case Scenarios	• Case: 59M, 65 mL, High Volume GG1
9:00 am	Is There a Role for UroLift? Amin Herati, MD
9:10 am	Is There a Role for Temporary Urethral Stents? Karla Witzke, DO
9:20 am	What is the Role of HoLEP? Nicole Miller, MD
9:30 am	Discussion
PART 3 • Current and Fut	ure BPH Therapy
9:35 am	Aquablation: How I Do It Now Kevin Zorn, MD, FRCSC, FACS
9:40 am	Optilume BPH: How I Do It Now <i>Bilal Chughtai, MD</i>
9:45 am	HoLEP: How I Did It and How I Do It Now Nicole Miller, MD
9:50 am	Discussion
10:00 am – 10:30 am	COFFEE BREAK WITH EXHIBITORS • Seaport Ballroom ABC



FRIDAY, OCTOBER 18 continued

* Ticketed Hands-On Course. Additional fee applies.

*BPH MANAGEMENT LIVE HANDS-ON LAB • Seaport Ballroom H		
10:30 am – 12:00 pm	Live Hands-On Training	
12:00 pm - 1:00 pm	LUNCH • Industry Sponsored Product Theater • Seaport Ballroom FG	
SESSION 3: INTRODUCTION TO FOCAL THERAPY		
1:00 pm	The Changing Landscape of Focal Therapy for Prostate Cancer Herbert Lepor, MD	
1:20 pm	Patient Selection: How to Pick a Focal Therapy Candidate? Derek Lomas, MD	
1:35 pm	Discussion	
1:45 pm	Energy Selection: Ablative Technologies for Focal Therapy Andre Abreu, MD	
2:05 pm	Point Counterpoint: Is Focal Therapy Ready for Prime Time? Yes Ruben Olivares, MD No Michael Rothberg, MD	
2:20 pm	Panel Discussion: Patient and Treatment Selection Moderator Abhinav Sidana, MD, MPH Panelists Andre Abreu, MD, Herbert Lepor, MD, Derek Lomas, MD, Ruben Olivares, MD, Michael Rothberg, MD	
3:00 pm - 3:30 pm	COFFEE BREAK WITH EXHIBITORS • Seaport Ballroom ABC	
SESSION 4: OUTCOMES AND SURVEILLANCE OF FOCAL THERAPY		
3:30 pm	Outcomes of Recent Clinical Trials for Focal Therapy Derek Lomas, MD	
3:50 pm	Optimal Surveillance Algorithm for Focal Therapy Herbert Lepor, MD	
4:00 pm	Interpretation of Post Focal Therapy Imaging: Target and Pifab Sadhna Verma, MD, MBA, FSAR	
4:20 pm	Discussion	
4:30 pm - 5:30 pm	BALLOON DEBATE: FOCAL FAILURE Moderator Abhinav Sidana, MD, MPH	
	Focal Prostate Ablation Amir Lebastchi, MD Whole Gland Prostate Ablation Aaron Katz, MD Watchful Waiting/Active Surveillance Arvin K. George, MD Radiation Therapy Daniel Song, MD Radical Prostatectomy Peter A. Pinto, MD	
5:30 pm – 6:00 pm	POSTER SESSION RECEPTION • Seaport Foyer	
Poster 01	Robot Assisted Focal Ablation (RAFA) Using Cryotherapy for Prostate Cancer: Initial Experience Louis S. Liou	
Poster 02	Augmented Triphasic Visualization of Rezum BPH Treatment in the OR and Office Louis S. Liou	
Poster 03	Early Outcomes for Office Based Targeted Laser Ablation for Prostate Cancer Based on NCCN Risk Stratification <i>Sijo J. Parekattil, MD</i>	
Poster 04	Role of Confirmatory Transperineal Mapping Biopsy in Men with Localized Prostate Cancer Eligible for Partial Gland Ablation Using High Intensity Focused Ultrasound Wan Song, MD, PhD	
Poster 05	Detection of In-field Clinically-Significant Prostate Cancer Recurrence Through the Use of the Prostate Imaging After Focal Ablation (PI-FAB) Score for Post-Treatment Prostate Magnetic Resonance Imaging Thomas Frye, DO	

All times listed in PT
Plenary Session • Seaport Ballroom DE

FRIDAY, OCTOBER 18 continued

Poster 06	Retrospective Analysis of MRI-Guided Transurethral Ultrasound Ablation (TULSA) in Men with Recurrent Prostate Cancer <i>Joseph J. Busch</i>
Poster 08	Head-to-Head Comparison of Biparametric versus Multiparametric MRI Sensitivity for Prostate Cancer Diagnosis in 3123 Patients: A Systematic Review and Meta-Analysis <i>Carlos A. Garcia Becerra, MD</i>
Poster 09	Our Initial Experience of Focal and Hemiablation with High Intensity Focused Ultrasound (HIFU) of Unilateral Localized Prostate Cancer: First Indian Experience Yuvaraja Thyavihally
Poster 10	Experience with Focal Therapy in a Large Urban Community Hospital Christopher Edwards, MD
Poster 11	Focal HDR Brachytherapy for Prostate Cancer: Minimizing Side Effects and with Effective Local Control Ida Danesh
Poster 12	Preliminary Medium-Term Outcomes of Histoblast, a Novel HIFU Technique for Benign Prostatic Hyperplasia Treatment <i>Carlos M. Garcia Gutierrez, MD</i>
Poster 13	Salvage Cryoablation for Radiorecurrent Prostate Cancer: A 19-Year Single Institution Experience Kit Yuen, MD
Poster 14	Performance of an Al-Assisted Prostate Segmentation Module for MRI-Guided Transurethral Ultrasound (TULSA) Treatment Planning: Multi-Reader Multi-Case Study Sandeep Arora
Poster 15	Artificial Intelligence Prostate Segmentation Integrated into Treatment Planning Software for MRI-Guided Transurethral Ultrasound Ablation (TULSA): Initial Real-World Experience Joseph J. Busch
Poster 16	Transperineal Prostate Biopsy – Prognostic Factors for No Prostate Tissue in Biopsy Cores David Nusbaum, MD
Poster 17	Incidence of Ideal Candidates for Focal Therapy in the MRI-Era Jae Woong Jang
Poster 20	Clinical Implications of Outpatient, Transrectal, MRI-Guided Laser Focal Therapy of Localized Prostate Cancer in an HIV Positive Patient: A Case Study Bernadette M. Greenwood
Poster 21	Clinically Significant Prostate Cancer Detection by Transperineal vs. Transrectal Magnetic Resonance Imaging Fusion Targeted Biopsy: Performance Among Possible Focal Therapy Candidates Adam Lin
Poster 22	MRI-Visible Prostate Cancer and Its Implications for Pathological Progression During Active Surveillance Andre Luis Abreu
Poster 23	Prostate Cancer Index Lesion Reclassification Artificial Intelligence: A Novel Lightweight Machine Learning for Biparametric MRI <i>Andre Luis Abreu</i>
Poster 24	PIRADS Lesions in Patients on Prostate Cancer Active Surveillance are Associated with Intermediate-Risk Pathology and Rarely Harbor High-Risk Disease <i>Ashley Vaughan</i>
Poster 25	Performance of mpMRI in the Detection of Clinically Significant Residual or Recurrent Cancer After Focal Therapy for Prostate Cancer <i>Simon Han</i>
Poster 26	Single Surgeon Experience with Procept Aquabeam Aquablation of the Prostate for Men with BPH: Five-Year Experience Ali Kasraeian, MD, MHA, FACS
Poster 27	Role of Prostate MR in the Performance and Surveillance of MR Guided Focal HDR Brachytherapy Jorge Abreu-Gomez
Poster 28	A Comparative Analysis Between the Conventional Posterior Reconstruction Technique and a Novel Technique Pioneered by Our Institution During Robot-Assisted Radical Prostatectomy Akinyemi Olalekan Samuel
Poster 40	Prospective, Multicenter, Single-Arm Study of Water Vapor Ablation for PrOstate CanceR (VAPOR2 Study) Michael Ayenew, MD

NETWORKING RECEPTION WITH EXHIBITORS

5:30 PM – 7:00 PM SEAPORT BALLROOM ABC



SATURDAY, OCTOBER 19 continued

* Ticketed Hands-On Course. Additional fee applies.

6:45 am – 4:30 pm	Registration & Information • Seaport Foyer	
7:00 am – 8:00 am	BREAKFAST • Industry Sponsored Product Theater • Seaport Ballroom FG	
SESSION 5: FOCAL THERAPY CHALLENGES AND CASE DISCUSSIONS		
8:00 am	Results of the PRIME Trial: Biparametric Versus Multiparametric MRI for Prostate Cancer Detection - Implications for Focal Therapy Veeru Kasivisvanathan, MBBS, BSc, FRCS, PhD, MSc, PGCert BSc, FRCS, PhD, MSc, PGCert	
8:20 am	Complications of Focal Therapy - Risk Factors, Timepoints, Management Amir Lebastchi, MD	
8:40 am	Mechanisms and Management of Recurrences Abhinav Sidana, MD, MPH	
9:00 am	Case Discussions Moderator Arvin K. George, MD Panelists Julien Anract, MD, Jonathan Fainberg, MD, MPH, Amir Lebastchi, MD, Abhinav Sidana, MD, MPH	
9:40 am -10:10 am	KEYNOTE LECTURE • Introduction of Disruptive Technologies: The Lessons From the Minimally Invasive Surgery Ralph Clayman, MD	
10:10 am - 10:40 am	COFFEE BREAK WITH EXHIBITORS • Seaport Ballroom ABC	
* LIVE HANDS-ON COURSE II • Seaport Ballroom H FUSION GUIDED ABLATION		
10:40 am - 12:00 pm	Hands-On Fusion Guided Ablation	
12:00 pm - 1:00 pm	LUNCH • Industry Sponsored Product Theater • Seaport Ballroom FG	
	* LIVE HANDS-ON COURSE III • Seaport Ballroom H TRANSPERINEAL PROSTATE INTERVENTIONS	
1:00 pm - 2:20 pm	Hands-On Transperineal Prostate Interventions	
	Hands-On Transperineal Prostate Interventions AFTERNOON BREAK – ON YOUR OWN	
2:20 pm - 2:30 pm		
2:20 pm - 2:30 pm	AFTERNOON BREAK – ON YOUR OWN	
2:20 pm - 2:30 pm 2:30 pm - 2:45 pm	AFTERNOON BREAK – ON YOUR OWN Oral Abstract Presentations Moderator Michael Rothberg, MD Oncological and Functional Outcomes Post Focal Low-Dose-Rate Brachytherapy for Low-Intermediate Risk Prostate Cancer – Results from Australia's LIBERATE Registry	
2:20 pm - 2:30 pm 2:30 pm - 2:45 pm 2:30 pm	AFTERNOON BREAK – ON YOUR OWN Oral Abstract Presentations Moderator Michael Rothberg, MD Oncological and Functional Outcomes Post Focal Low-Dose-Rate Brachytherapy for Low-Intermediate Risk Prostate Cancer – Results from Australia's LIBERATE Registry Mohammadmehdi Adhami, MD Spatial Characterization and Al-Driven Prevention of Residual Cancer Following Focal Therapy	
2:20 pm - 2:30 pm 2:30 pm - 2:45 pm 2:30 pm	AFTERNOON BREAK – ON YOUR OWN Oral Abstract Presentations Moderator Michael Rothberg, MD Oncological and Functional Outcomes Post Focal Low-Dose-Rate Brachytherapy for Low-Intermediate Risk Prostate Cancer – Results from Australia's LIBERATE Registry Mohammadmehdi Adhami, MD Spatial Characterization and Al-Driven Prevention of Residual Cancer Following Focal Therapy Preston Sprenkle, MD Best Clinical Practices for Transperineal Prostate Biopsy: Results from an International	
2:20 pm - 2:30 pm 2:30 pm - 2:45 pm 2:30 pm 2:35 pm 2:40 pm	AFTERNOON BREAK – ON YOUR OWN Oral Abstract Presentations Moderator Michael Rothberg, MD Oncological and Functional Outcomes Post Focal Low-Dose-Rate Brachytherapy for Low-Intermediate Risk Prostate Cancer – Results from Australia's LIBERATE Registry Mohammadmehdi Adhami, MD Spatial Characterization and Al-Driven Prevention of Residual Cancer Following Focal Therapy Preston Sprenkle, MD Best Clinical Practices for Transperineal Prostate Biopsy: Results from an International Delphi Consensus. Andre Luis Abreu, MD	

All times listed in PT Plenary Session • Seaport Ballroom DE

SATURDAY, OCTOBER 19 continued

SESSION 6: CONTROVERSIES IN PROSTATE CANCER	
3:10 pm	Diet and Prostate Cancer: What We Need to Know to Tell our Patients? Stacy Loeb, MD, MSc, PhD (Hon) (Hon), MD
3:25 pm	Role of Whole Gland Ablation in Prostate Cancer James Wysock, MD
3:40 pm	Starting a Transperineal Prostate Biopsy Program: Cost Effective Strategy for Implementation Richard Wu, MD
3:55 pm	CAPTAIN: A Randomized Controlled Trial of MRI-Guided Transurethral Ultrasound Ablation of the Prostate versus Radical Prostatectomy <i>Xiaosong Meng, MD, PhD</i>
4:05 pm	Conclusion Abhinav Sidana, MD, MPH



Thank You

FOCAL+2024 PARTNERSHIPS

DIAMOND



PLATINUM



angiodynamics



Focal·One



GOLD







BRONZE



































EXHIBITOR























